3:58 PM
 | 
Oct 02, 2018
 |  BC Extra  |  Financial News

Allogene IPO could be year's largest biotech listing on NASDAQ

In newly proposed terms for its planned IPO on NASDAQ, cell therapy start-up Allogene Therapeutics Inc. (South San Francisco, Calif.) hopes to sell 16 million shares at $16-$18. At the midpoint, Allogene would raise $272 million and be valued at $1.9 billion.

Allogene had filed on Sept. 14 to raise up to $100...

Read the full 247 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >